Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 3
1952 12
1953 63
1954 68
1955 37
1956 40
1957 49
1958 33
1959 25
1960 17
1961 15
1962 26
1963 51
1964 65
1965 40
1966 27
1967 45
1968 30
1969 51
1970 48
1971 54
1972 58
1973 74
1974 107
1975 89
1976 88
1977 109
1978 138
1979 147
1980 213
1981 194
1982 191
1983 224
1984 213
1985 219
1986 184
1987 151
1988 160
1989 135
1990 128
1991 143
1992 138
1993 135
1994 114
1995 119
1996 110
1997 97
1998 82
1999 72
2000 84
2001 77
2002 85
2003 77
2004 86
2005 136
2006 108
2007 113
2008 112
2009 103
2010 84
2011 90
2012 89
2013 78
2014 105
2015 79
2016 90
2017 86
2018 69
2019 75
2020 71
2021 94
2022 89
2023 92
2024 54

Text availability

Article attribute

Article type

Publication date

Search Results

6,628 results

Results by year

Filters applied: . Clear all
Page 1
A review on the clinical pharmacokinetics of hydralazine.
Shahzad Qamar A, Zamir A, Khalid S, Ashraf W, Imran I, Hussain I, Rehman AU, Saeed H, Majeed A, Alqahtani F, Rasool MF. Shahzad Qamar A, et al. Expert Opin Drug Metab Toxicol. 2022 Oct;18(10):707-714. doi: 10.1080/17425255.2022.2129005. Epub 2022 Sep 27. Expert Opin Drug Metab Toxicol. 2022. PMID: 36150895 Review.
INTRODUCTION: Hydralazine is a vasodilator used to treat hypertension, pre-eclampsia, and heart failure. ...EXPERT OPINION: The current review will aid clinicians in understanding hydralazine PK in different disease populations. This clinical PK data might also be h …
INTRODUCTION: Hydralazine is a vasodilator used to treat hypertension, pre-eclampsia, and heart failure. ...EXPERT OPINION: The curre …
Hydralazine for essential hypertension.
Kandler MR, Mah GT, Tejani AM, Stabler SN, Salzwedel DM. Kandler MR, et al. Cochrane Database Syst Rev. 2011 Nov 9;(11):CD004934. doi: 10.1002/14651858.CD004934.pub4. Cochrane Database Syst Rev. 2011. PMID: 22071816 Review.
SELECTION CRITERIA: We selected RCTs studying the effect of oral hydralazine compared to oral placebo in patients with primary hypertension. ...MAIN RESULTS: The search strategy did not yield any randomized controlled trials comparing hydralazine to placebo for incl …
SELECTION CRITERIA: We selected RCTs studying the effect of oral hydralazine compared to oral placebo in patients with primary hypert …
Hydralazine-induced lupus.
Singh S. Singh S. South Med J. 2006 Jan;99(1):6-7. doi: 10.1097/01.smj.0000197302.13225.08. South Med J. 2006. PMID: 16466108 No abstract available.
Drug therapy. Hydralazine.
Koch-Weser J. Koch-Weser J. N Engl J Med. 1976 Aug 5;295(6):320-3. doi: 10.1056/NEJM197608052950606. N Engl J Med. 1976. PMID: 778618 Review. No abstract available.
HYDRALLAZINE.
[No authors listed] [No authors listed] Lancet. 1977 Feb 12;1(8007):342-3. Lancet. 1977. PMID: 64864 No abstract available.
Parenteral hydralazine revisited.
Powers DR, Papadakos PJ, Wallin JD. Powers DR, et al. J Emerg Med. 1998 Mar-Apr;16(2):191-6. doi: 10.1016/S0736-4679(97)00287-4. J Emerg Med. 1998. PMID: 9543400 Free article. Review.
It is reiterated that parenteral hydralazine is the preferred drug for the treatment of severe preeclampsia, but its usefulness in other forms of accelerated hypertension is also addressed. Through comparisons with other established antihypertensive agents, the efficacy an …
It is reiterated that parenteral hydralazine is the preferred drug for the treatment of severe preeclampsia, but its usefulness in ot …
Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Dueñas-Gonzalez A, Coronel J, Cetina L, González-Fierro A, Chavez-Blanco A, Taja-Chayeb L. Dueñas-Gonzalez A, et al. Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1433-44. doi: 10.1517/17425255.2014.947263. Epub 2014 Aug 25. Expert Opin Drug Metab Toxicol. 2014. PMID: 25154405 Review.
So far, four epigenetic drugs are approved for myelodysplastic syndrome (MDS) and cutaneous T-cell lymphoma (CTCL). The combination of hydralazine-valproate (TRANSKRIP()) is being repositioned as an oral DNMT and HDAC inhibitor. ...Studies on MDS and CTCL would also eventu …
So far, four epigenetic drugs are approved for myelodysplastic syndrome (MDS) and cutaneous T-cell lymphoma (CTCL). The combination of hy …
Metabolism of hydralazine.
Israili ZH, Dayton PG. Israili ZH, et al. Drug Metab Rev. 1977;6(2):283-305. doi: 10.3109/03602537708997482. Drug Metab Rev. 1977. PMID: 344023 Review. No abstract available.
Hydralazine-induced lupus: maintaining vigilance with increased use in patients with heart failure.
Finks SW, Finks AL, Self TH. Finks SW, et al. South Med J. 2006 Jan;99(1):18-22. doi: 10.1097/01.smj.0000197121.12352.19. South Med J. 2006. PMID: 16466117 Review.
OBJECTIVE: To review data concerning the incidence and danger of hydralazine-induced systemic lupus erythematosus (SLE) and review how best to monitor patients placed on chronic hydralazine therapy. ...Patients should be closely monitored when initiating hydralaz …
OBJECTIVE: To review data concerning the incidence and danger of hydralazine-induced systemic lupus erythematosus (SLE) and review ho …
Drug-induced peripheral neuropathies.
Burley D, Steen J. Burley D, et al. Br Med J. 1979 Apr 21;1(6170):1082. doi: 10.1136/bmj.1.6170.1082-c. Br Med J. 1979. PMID: 221064 Free PMC article. No abstract available.
6,628 results